Skip to Content
Merck
CN
  • Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.

Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.

Acta cardiologica (2014-05-03)
Daisy Puttevils, Philip De Vusser, Piet Geusens, Jo Dens
ABSTRACT

Patients with established rheumatoid arthritis (RA) have a higher cardiovascular morbidity and mortality in comparison with the general population. It is considered to be an independent risk factor for cardiovascular disease. The purpose of this article is to describe the mechanisms responsible for accelerated atherogenesis in RA patients and to give an overview of the effects of different RA therapies (methotrexate, TNF antagonists and other biologicals).

MATERIALS
Product Number
Brand
Product Description

Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Methotrexate hydrate, ≥99.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
Methotrexate hydrate, ≥98% (HPLC), powder
Sigma-Aldrich
Methotrexate, meets USP testing specifications
Sigma-Aldrich
Methotrexate hydrate, powder, BioReagent, suitable for cell culture, ≥98% (HPLC)
Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Methotrexate solution, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
Methotrexate, European Pharmacopoeia (EP) Reference Standard
Supelco
Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material
SAFC
Methotrexate